Search

Your search keyword '"Aschero, Simona"' showing total 14 results
Start Over Author "Aschero, Simona"
14 results on '"Aschero, Simona"'

2. MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients

Author

Rocci, Alberto, Gambella, Manuela, Aschero, Simona, Baldi, Ileana, Trusolino, Livio, Cavallo, Federica, Gay, Francesca, Larocca, Alessandra, Magarotto, Valeria, Omedè, Paola, Isaia, Gianluca, Bertotti, Andrea, Liberati, Anna M., Catalano, Lucio, De Rosa, Luca, Musto, Pellegrino, Vallone, Roberto, Falcone, Antonietta, Drandi, Daniela, Ladetto, Marco, Comoglio, Paolo M., Boccadoro, Mario, and Palumbo, Antonio

Published
2014
Full Text
View/download PDF

3. Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study

Author

Bringhen, Sara, primary, Oliva, Stefania, additional, Liberati, Anna Marina, additional, Belotti, Angelo, additional, Larocca, Alessandra, additional, Bonello, Francesca, additional, Gaidano, Gianluca, additional, Bertazzoni, Paola, additional, Esma, Fabrizio, additional, Stocchi, Raffaella, additional, Malfitano, Alessandra, additional, Ribolla, Rossella, additional, Di Sano, Chiara, additional, Aschero, Simona, additional, Patriarca, Francesca, additional, De Paoli, Lorenzo, additional, Cafro, Anna Maria, additional, Sonneveld, Pieter, additional, Palumbo, Antonio, additional, and Boccadoro, Mario, additional

Published
2017
Full Text
View/download PDF

4. Weekly Carfilzomib, Cyclophosphamide and Dexamethasone (wCCyd) in Elderly Newly Diagnosed Multiple Myeloma Patients: Results of a Phase 2 Study

Author

Bringhen, Sara, primary, Rossi, Davide, additional, Larocca, Alessandra, additional, Corradini, Paolo, additional, Galieni, Piero, additional, Malfitano, Alessandra, additional, Aschero, Simona, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Genuardi, Mariella, additional, Gaidano, Gianluca, additional, Palladino, Carmela, additional, Gentilini, Fabiana, additional, Boccadoro, Mario, additional, Sonneveld, Pieter, additional, and Palumbo, Antonio, additional

Published
2015
Full Text
View/download PDF

6. Analisi genomica del medulloblastoma in pazienti pediatrici

Author

Coco, S, Pezzolo, A, Capra, V, Raso, A, Nozza, P, Longo, L, Cama, A, Gambini, C, Pistoia, V, Sandri, A, Basso, Me, Aschero, Simona, Forni, M, Madon, Enrico, Garrè, Ml, Cinalli, G, Andolfo, I, Zollo, M, Iolascon, A, and Tonini, Gp

Subjects
medulloblastoma, pazienti pediatrici
Published
2007

9. A Phase III Study Of ASCT Vs Cyclophosphamide-Lenalidomide-Dexamethasone and Lenalidomide-Prednisone Maintenance Vs Lenalidomide Alone In Newly Diagnosed Myeloma Patients

Author

Palumbo, Antonio, primary, Gay, Francesca, additional, Spencer, Andrew, additional, Di Raimondo, Francesco, additional, Zdenek, Adam, additional, Larocca, Alessandra, additional, Falcone, Antonietta Pia, additional, Catalano, Lucio, additional, Finsinger, Paola, additional, Vlastimil, Scudla, additional, Aschero, Simona, additional, Offidani, Massimo, additional, Liberati, Anna Marina, additional, Carella, Angelo Michele, additional, Vladimir, Maisnar, additional, Donato, Francesca, additional, Caravita, Tommaso, additional, Corradini, Paolo, additional, Ria, Roberto, additional, Pulini, Stefano, additional, Stocchi, Raffaella, additional, Conticello, Concetta, additional, Petrucci, Maria Teresa, additional, Hajek, Roman, additional, and Boccadoro, Mario, additional

Published
2013
Full Text
View/download PDF

10. Loss of 10q26.1–q26.3 in association with 7q34–q36.3 gain or 17q24.3–q25.3 gain predict poor outcome in pediatric medulloblastoma

Author

Pezzolo, Annalisa, primary, Coco, Simona, additional, Raso, Alessandro, additional, Parodi, Federica, additional, Pistorio, Angela, additional, Valdora, Francesca, additional, Capra, Valeria, additional, Zollo, Massimo, additional, Aschero, Simona, additional, Basso, Eleonora, additional, Cama, Armando, additional, Nozza, Paolo, additional, Gambini, Claudio, additional, Cinalli, Giuseppe, additional, Garrè, Maria Luisa, additional, Iolascon, Achille, additional, Pistoia, Vito, additional, and Tonini, Gian Paolo, additional

Published
2011
Full Text
View/download PDF

11. High Expression of mRNA and Gene Amplification of Met In Myeloma Plasma Cells Characterize a More Aggressive Disease

Author

Rocci, Alberto, primary, Gambella, Manuela, additional, Aschero, Simona, additional, Baldi, Ileana, additional, Trusolino, Livio, additional, Cavallo, Federica, additional, Larocca, Alessandra, additional, Omedè, Paola, additional, Bertotti, Andrea, additional, Montefusco, Vittorio, additional, Crippa, Claudia, additional, Patriarca, Francesca, additional, Liberati, Anna Marina, additional, Falcone, Antonietta, additional, Isaia, Gianluca, additional, Drandi, Daniela, additional, Ladetto, Marco, additional, Comoglio, Paolo M., additional, Ciccone, Giovannino, additional, Boccadoro, Mario, additional, and Palumbo, Antonio, additional

Published
2010
Full Text
View/download PDF

13. Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies.

Author

Caltagirone S, Ruggeri M, Aschero S, Gilestro M, Oddolo D, Gay F, Bringhen S, Musolino C, Baldini L, Musto P, Petrucci MT, Gaidano G, Passera R, Bruno B, Palumbo A, Boccadoro M, and Omedè P

Subjects
Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Humans, Immunophenotyping, In Situ Hybridization, Fluorescence, Middle Aged, Multiple Myeloma drug therapy, Multiple Myeloma mortality, Odds Ratio, Retrospective Studies, Treatment Outcome, Chromosome Aberrations, Chromosomes, Human, Pair 1, Multiple Myeloma diagnosis, Multiple Myeloma genetics
Abstract

Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or urine monoclonal protein and organ damage. The aim of this study was to investigate the impact of chromosome 1 abnormalities in a group of elderly patients (>65 years) with newly diagnosed multiple myeloma enrolled in the GIMEMA-MM-03-05 trial and treated with bortezomib, melphalan and prednisone or bortezomib, melphalan, prednisone and thalidomide followed by bortezomib and thalidomide maintenance. We also evaluated the link between chromosome 1 abnormalities and other clinical, genetic and immunophenotypic features by a multivariate logistic regression model. Interphase fluorescence in situ hybridization on immunomagnetically purified plasma cells and bone marrow multiparameter flow cytometry were employed. A multivariate Cox model showed that chromosome 1 abnormalities, age >75 years and a CD19(+)/CD117(-) immunophenotype of bone marrow plasma cells were independent risk factors for overall survival in elderly patients with newly diagnosed multiple myeloma. Moreover, a detrimental effect of thalidomide, even when administered in association with bortezomib, was observed in patients with abnormal chromosome 1 as well as in those with 17p deletion, while the benefit of adding thalidomide to the bortezomib-melphalan-prednisone regimen was noted in patients carrying an aggressive CD19(+)/CD117(-) bone marrow plasma cell immunophenotype. This trial was registered at www.clinicaltri-als.gov as #NCT01063179., (Copyright© Ferrata Storti Foundation.)

Published
2014
Full Text
View/download PDF

14. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow.

Author

Mareschi K, Ferrero I, Rustichelli D, Aschero S, Gammaitoni L, Aglietta M, Madon E, and Fagioli F

Subjects
Adult, Bone Marrow chemistry, Cell Culture Techniques, Cell Survival, Child, Female, Flow Cytometry, Humans, Immunophenotyping, Karyotyping, Male, Mesenchymal Stem Cells chemistry, Mesenchymal Stem Cells metabolism, Middle Aged, Telomere physiology, Tissue Donors, Antigens, CD metabolism, Bone Marrow Cells chemistry, Cell Proliferation, Mesenchymal Stem Cells physiology
Abstract

The enormous plasticity of mesenchymal stem cells (MSCs) suggests an improvement of a standard protocol of isolation and ex vivo expansion for experimental and clinical use. We isolated and expanded MSCs from bone marrow (BM) of pediatric and young adult donors, to analyze the growth kinetic, immunophenotype, telomere length, karyotype during ex vivo expansion. Seventeen BM samples were collected from young adult donors and 8 from pediatric donors. MSCs isolated from two groups showed no morphological differences while their cell growth was strictly related to the donor's age. The MSCs isolated from pediatric donors reached a cumulative PD almost twice as high as MSCs isolated from young adult donors after 112 days (10.2 +/- 1.9 versus 5.5 +/- 3.7). Furthermore, we analyzed the modulation of antigen expression in the MSCs isolated from two groups until 10th passage (77 days) and there was no significant difference between the modulation of antigen expression. In particular, at the first passage, MSCs showed a low contamination of hemopoietic cells which became insignificant in the following passages. There was a high expression of CD90, CD29, CD44 and CD105 and variable and moderate expression of CD166 and CD106 at the start of MSC culture and at each passage during expansion. No chromosomal alteration or evidence of cellular senescence were observed in all analyzed samples. All these data suggest that MSCs can be isolated and expanded from most healthy donors, providing for an autologous source of stem cells., (2005 Wiley-Liss, Inc.)

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results